- Home
- MLYS vs CRML Comparison
MLYS vs CRML Comparison
Compare MLYS & CRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- CRML
- Stock Information
- Founded
- MLYS 2019
- CRML N/A
- Country
- MLYS United States
- CRML United States
- Employees
- MLYS N/A
- CRML N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- CRML
- Sector
- MLYS Health Care
- CRML
- Exchange
- MLYS Nasdaq
- CRML NYSE
- Market Cap
- MLYS 526.1M
- CRML 635.6M
- IPO Year
- MLYS 2023
- CRML N/A
- Fundamental
- Price
- MLYS $10.21
- CRML $8.57
- Analyst Decision
- MLYS Strong Buy
- CRML
- Analyst Count
- MLYS 2
- CRML 0
- Target Price
- MLYS $30.00
- CRML N/A
- AVG Volume (30 Days)
- MLYS 263.5K
- CRML 117.4K
- Earning Date
- MLYS 03-20-2025
- CRML 02-01-2025
- Dividend Yield
- MLYS N/A
- CRML N/A
- EPS Growth
- MLYS N/A
- CRML N/A
- EPS
- MLYS N/A
- CRML N/A
- Revenue
- MLYS N/A
- CRML $117,660.00
- Revenue This Year
- MLYS N/A
- CRML N/A
- Revenue Next Year
- MLYS N/A
- CRML N/A
- P/E Ratio
- MLYS N/A
- CRML N/A
- Revenue Growth
- MLYS N/A
- CRML 5.79
- 52 Week Low
- MLYS $8.58
- CRML $5.32
- 52 Week High
- MLYS $16.91
- CRML $22.50
- Technical
- Relative Strength Index (RSI)
- MLYS 44.53
- CRML 53.88
- Support Level
- MLYS $9.57
- CRML $7.00
- Resistance Level
- MLYS $10.79
- CRML $8.20
- Average True Range (ATR)
- MLYS 0.64
- CRML 0.92
- MACD
- MLYS 0.11
- CRML -0.01
- Stochastic Oscillator
- MLYS 63.98
- CRML 43.06
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.